Skip to main content
SpyGlass Pharma, Inc. logo

SpyGlass Pharma, Inc. — Investor Relations & Filings

Ticker · SGP ISIN · US85220G1094 Professional, scientific and technical activities
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing — SGP

About SpyGlass Pharma, Inc.

https://spyglasspharma.com/

SpyGlass Pharma, Inc. is an ophthalmic biotechnology company focused on developing a proprietary drug delivery platform for the treatment of chronic eye diseases, specifically glaucoma and cataracts. The company’s core technology is a non-bioerodible drug delivery system integrated with an intraocular lens (IOL), designed to provide sustained medical therapy for up to three years. By delivering medication directly to targeted ocular tissues during standard cataract surgery, the platform aims to address patient compliance issues and the treatment gap associated with daily topical therapies. Clinical data for its lead program, which utilizes bimatoprost, demonstrates significant reduction in intraocular pressure. SpyGlass Pharma focuses on providing long-term, automated management of ophthalmic conditions to improve patient outcomes and simplify treatment regimens for those with mild-to-moderate glaucoma.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Report Publication Announcement Classification · 88% confidence The document is a short (approx. 3,500 characters) SEC Form 8-K that merely states SpyGlass Pharma issued a press release announcing its quarterly financial results and that the release is furnished as Exhibit 99.1. It does not include any substantive financial data itself, only noting the press release is attached. Under the "menu vs. meal" rule for very brief filings that announce and attach a report rather than containing the report content, this is a Report Publication Announcement (RPA).
2026-05-14 English
10-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
Annual Report FY 2025
2026-03-26 English
8-K - SPYGLASS PHARMA, INC. (0001778922) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the approval and disclosure of performance cash bonuses for named executive officers for fiscal year 2025, including an updated Summary Compensation Table. This relates to changes or updates in executive compensation and officer information. The key section is Item 5.02, which deals with departure, election, or appointment of directors or officers and compensatory arrangements. The document is not a full annual report, audit report, or earnings release, but rather a regulatory filing announcing specific management and compensation information. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (6783 characters) and detailed compensation table confirm it is not a brief announcement or certification but a substantive filing about management changes and compensation.
2026-02-13 English
4 - SPYGLASS PHARMA, INC. (0001778922) (Filer)
Director's Dealing
2026-02-11 English
4 - SPYGLASS PHARMA, INC. (0001778922) (Filer)
Director's Dealing
2026-02-11 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.